Unicharm (OTCMKTS:UNICY - Get Free Report) issued an update on its FY 2025 earnings guidance on Thursday morning. The company provided earnings per share (EPS) guidance of 0.320-0.320 for the period. The company issued revenue guidance of $6.7 billion-$6.7 billion.
Unicharm Price Performance
Unicharm stock traded down $0.23 during mid-day trading on Monday, reaching $3.88. 336,658 shares of the company were exchanged, compared to its average volume of 746,761. The company has a fifty day simple moving average of $4.32 and a 200-day simple moving average of $5.70. The firm has a market cap of $11.38 billion, a PE ratio of 19.40 and a beta of 0.22. Unicharm has a 12 month low of $3.54 and a 12 month high of $8.10.
About Unicharm
(
Get Free Report)
Unicharm Corporation engages in the manufacturing and sale of wellness, feminine, baby and children, kirei, and pet care products in Japan and internationally. The company's baby and child care products, including disposable diapers and wipes under the Moony, MamyPoko, Oyasumiman, and Torepanman brands; feminine care products comprise napkins, tampons, panty liners, sanitary short, panty liners, and other feminine care products under the Sofy, Center-In, and Unicharm brand names; and wellness care products include napkin-type incontinence pads, pants-type diapers, tape-type diapers, pants-type specialized urine pads, and tape-type specialized urine pads under the Lifree and Charmnap brand.
See Also
Before you consider Unicharm, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Unicharm wasn't on the list.
While Unicharm currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
